<pad> The high efficacy found in the clinical trials to date has precluded identification of a minimum protective antibody titer.Quadrivalent HPV Vaccine (HPV4)HPV4 EfficacyFemales Aged 16–26 yearsThree randomized, double-blind, placebo-controlled clinical trials evaluated the efficacy of HPV4 for prevention of HPV-associated disease: a phase II trial (protocol 007) among females aged 16–23 years (113), and two phase III trials (protocols 013 and 015) among females aged 16–24 and 15–26 years, respectively (114, 115).</s>